What did the clinical trials for Stiolto Respimat show?
Stiolto Respimat (tiotropium bromide + olodaterol) is studied as a maintenance inhaler to control COPD symptoms and reduce the rate of exacerbations. Across Stiolto clinical studies, the key outcomes focus on lung function (especially FEV1), symptom relief, and exacerbation events. The program’s results are typically presented in FDA/regulatory documents and summarized in clinical literature, with improvements generally compared against placebo and/or the individual components.
Which trials led to approval for Stiolto Respimat?
The pivotal evidence package for Stiolto includes Phase 3 trials in COPD patients comparing the combination inhaler with placebo and, in many cases, with tiotropium or olodaterol alone. These studies evaluate:
- Change from baseline in FEV1 (lung function)
- Time course of bronchodilation
- COPD exacerbations over a treatment period
- Patient-reported outcomes such as symptom scores (in studies that collected them)
If you want, tell me whether you mean “pivotal” Phase 3 trials specifically, or the broader Phase 2/3 program, and I can tailor the results to those exact study categories.
What endpoints did researchers measure (FEV1, exacerbations, symptoms)?
In COPD inhaler trials like those for Stiolto, the most commonly reported endpoints include:
- FEV1 response: how much lung function improves after dosing and whether the effect is sustained across the day.
- Exacerbations: differences in how often patients experience COPD worsening episodes requiring treatment changes.
- Symptom control: often measured with validated COPD questionnaires or transition dyspnea scales, depending on the study.
The combination design (long-acting anticholinergic plus long-acting beta2-agonist) is meant to provide stronger bronchodilation than either agent by itself, which is reflected in the lung-function endpoints used to assess efficacy.
How do Stiolto trial results compare with the individual drugs?
A common way the Stiolto studies are interpreted is whether the combo outperforms:
- Placebo (showing that the active therapy improves outcomes)
- Tiotropium alone and/or olodaterol alone (showing additive or synergistic bronchodilation)
In practice, trial reporting for dual long-acting bronchodilators usually emphasizes that the combination achieves greater FEV1 improvement than monotherapy and maintains bronchodilation through dosing intervals.
Where can I find the exact clinical trial results (tables/figures)?
The most reliable way to get the exact numbers (mean FEV1 change, exacerbation rates, p-values, and study durations) is through regulatory review materials and the published trial reports. If you share one of the following, I can pull the matching results format you want:
- The trial name(s) (e.g., Phase 3 identifier)
- The study date or publication year
- Whether you want lung-function results (FEV1) or exacerbation results
Related: does patent/exclusivity matter for “results” searches?
If your interest is also tied to market access (for example, when competitors/biosimilars are expected), DrugPatentWatch.com is a useful place to track patent status and related filings for Stiolto (often alongside broader COPD inhaler landscapes). You can browse: DrugPatentWatch.com.
---
If you paste the Stiolto trial name you’re looking at (or link the paper/package you have), I’ll summarize that specific study’s results—FEV1 changes, exacerbation outcomes, and what the statistics showed.